HIV-1 integrase strand transfer inhibitors and neurodevelopment

EG Foster, HE Gendelman, AN Bade - Pharmaceuticals, 2022 - mdpi.com
Children born to mothers, with or at risk, of human immunodeficiency virus type-1 (HIV-1)
infection are on the rise due to affordable access of antiretroviral therapy (ART) to pregnant …

What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies

TG Jacobs, S Schouwenburg, M Penazzato… - The Lancet …, 2022 - thelancet.com
Although 23 antiretroviral drugs are approved for use in adults, only six are approved by
regulatory authorities for use in term neonates born to women with HIV, with even fewer …

Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial

TG Jacobs, V Mumbiro, U Cassia… - Clinical Infectious …, 2024 - academic.oup.com
Background We evaluated dolutegravir pharmacokinetics in infants with human
immunodeficiency virus (HIV) receiving dolutegravir twice daily (BID) with rifampicin-based …

Influence of age and co‐medication on dolutegravir glucuronidation in paediatric patients

TG Jacobs, H Waalewijn, L Houlden… - British journal of …, 2024 - Wiley Online Library
Dolutegravir (DTG) is primarily metabolized by uridine diphosphate
glucuronosyltransferases, forming the pharmacologically inactive DTG glucuronide (DTG …

[PDF][PDF] 19. Pregnancy and HIV

M VOCKS-HAUCK - Janssen-Cilag MSD ViiV Healthcare - hivbuch.de
HIV infection of the newborn has become rare in Western Europe and the United States
since the introduction of antiretroviral transmission prophylaxis and elective sectio. While the …